IKARIAN CAPITAL LLC
Q3 2026 Form 13-F

DALLAS, TEXAS
CIK 0001778253 · CRD 281880 · SEC-registered investment adviser
$994.2M Reported Value Total

IKARIAN CAPITAL reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $697,961,635, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $564.0M gross asset value
Hedge Fund: $564.0M
Source: Form ADV filed 2026-05-20
Reported value
$994.2M
Quarter over quarter
-8.8%
Holdings
125
Top-10 concentration
38.2%

Key People

Form ADV owners & control persons
Ryan David Atwell
CONTROLLER
Matthew G Hale
DEPUTY COMPLIANCE OFFICER
David Edward Kaufman
DIRECTOR OF BUSINESS DEVELOPMENT AND INVESTOR RELATIONS

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $994.2M
Positions 125
Change in reported value +7.1%
New positions 19
Exited positions 20
Position turnover 26.9%
Top-10 concentration 38.2%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
125 $994.2M
Q2 2026 13F
Filed Aug 14, 2026
126 $928.2M
Q1 2026 13F
Filed May 15, 2026
127 $1.2B
Q4 2025 13F
Filed Feb 18, 2026
135 $1.3B
Q3 2025 13F
Filed Nov 14, 2025
116 $990.4M
Q2 2025 13F
Filed Aug 14, 2025
103 $520.6M
Q1 2025 13F
Filed May 15, 2025
116 $811.5M
Q4 2024 13F
Filed Feb 14, 2025
122 $735.3M
Q3 2024 13F
Filed Nov 14, 2024
96 $717.2M
Q2 2024 13F
Filed Aug 14, 2024
85 $574.1M
Q1 2024 13F
Filed May 15, 2024
82 $912.0M
Q4 2023 13F
Filed Feb 14, 2024
78 $1.1B
Q3 2023 13F
Filed Nov 14, 2023
81 $831.4M
Q2 2023 13F
Filed Aug 14, 2023
81 $627.9M
Q1 2023 13F
Filed May 15, 2023
90 $440.7M
Q4 2022 13F
Filed Feb 14, 2023
66 $414.5M
Q3 2022 13F
Filed Nov 14, 2022
64 $501.8M
Q2 2022 13F
Filed Aug 12, 2022
97 $548.4M
Q1 2022 13F
Filed May 13, 2022
153 $760.5M
Q4 2021 13F
Filed Feb 14, 2022
149 $671.3M

8 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 MRNA P MODERNA INC $77.0M 7.75%
2 BMY P BRISTOL-MYERS SQUIBB CO $61.9M 6.23%
3 KOD KODIAK SCIENCES INC $50.5M 5.08%
4 XBI P SPDR SERIES TRUST $47.3M 4.76%
5 PRAX C PRAXIS PRECISION MEDICINES I $29.1M 2.92%
6 ABVX ABIVAX SA $28.4M 2.86%
7 IRON P DISC MEDICINE INC $25.5M 2.56%
8 PCVX VAXCYTE INC $22.8M 2.29%
9 RCUS ARCUS BIOSCIENCES INC $19.0M 1.91%
10 INCY P INCYTE CORP $18.2M 1.83%
11 ACAD C ACADIA PHARMACEUTICALS INC $17.1M 1.72%
12 PCVX P VAXCYTE INC $17.1M 1.72%
13 CLDX CELLDEX THERAPEUTICS INC NEW $16.8M 1.69%
14 AMLX AMYLYX PHARMACEUTICALS INC $16.3M 1.64%
15 PHVS PHARVARIS N V $15.9M 1.6%
16 KYMR P KYMERA THERAPEUTICS INC $14.9M 1.5%
17 KOD C KODIAK SCIENCES INC $14.2M 1.43%
18 IRON C DISC MEDICINE INC $13.1M 1.32%
19 VERA VERA THERAPEUTICS INC $12.9M 1.3%
20 ANRO ALTO NEUROSCIENCE INC $12.3M 1.24%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings